GenSight Biologics S.A.
SIGHT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €2,625 | €1,267 | €2,582 | €5,276 |
| % Growth | 107.2% | -50.9% | -51.1% | – |
| Cost of Goods Sold | €0 | -€1,733 | €0 | €0 |
| Gross Profit | €2,625 | €3,000 | €2,582 | €5,276 |
| % Margin | 100% | 236.8% | 100% | 100% |
| R&D Expenses | €12,368 | €19,360 | €18,938 | €22,554 |
| G&A Expenses | €5,386 | €6,499 | €8,006 | €5,680 |
| SG&A Expenses | €6,071 | €7,267 | €8,237 | €5,894 |
| Sales & Mktg Exp. | €685 | €768 | €231 | €214 |
| Other Operating Expenses | -€1 | €6,033 | €3,242 | €4,953 |
| Operating Expenses | €18,438 | €32,660 | €30,417 | €33,401 |
| Operating Income | -€15,813 | -€29,696 | -€27,835 | -€28,126 |
| % Margin | -602.4% | -2,343.8% | -1,078% | -533.1% |
| Other Income/Exp. Net | €1,833 | €3,475 | €215 | -€489 |
| Pre-Tax Income | -€13,980 | -€26,221 | -€27,619 | -€28,615 |
| Tax Expense | €21 | -€1 | €5 | €2 |
| Net Income | -€14,001 | -€26,220 | -€27,624 | -€28,617 |
| % Margin | -533.4% | -2,069.5% | -1,069.9% | -542.4% |
| EPS | -0.15 | -0.54 | -0.6 | -0.63 |
| % Growth | 72.2% | 10% | 4.8% | – |
| EPS Diluted | -0.15 | -0.54 | -0.6 | -0.63 |
| Weighted Avg Shares Out | 95,755 | 48,316 | 46,330 | 45,151 |
| Weighted Avg Shares Out Dil | 95,755 | 48,316 | 46,330 | 45,151 |
| Supplemental Information | – | – | – | – |
| Interest Income | €53 | €0 | €2,650 | €0 |
| Interest Expense | €1,553 | €3,153 | €2,650 | €2,166 |
| Depreciation & Amortization | €1,059 | €3,034 | €1,061 | €928 |
| EBITDA | -€14,755 | -€21,730 | -€26,774 | -€25,521 |
| % Margin | -562.1% | -1,715.1% | -1,036.9% | -483.7% |